OTCMKTS:ATRX Adhera Therapeutics (ATRX) Stock Price, News & Analysis $0.0080 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.0080▼$0.008050-Day Range$0.0011▼$0.017052-Week Range$0.00▼$0.06VolumeN/AAverage Volume27,831 shsMarket Capitalization$93,040.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsSEC FilingsShort Interest Get Adhera Therapeutics alerts: Email Address Ad American Hartford Gold GroupPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Adhera Therapeutics Stock (OTCMKTS:ATRX)Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.Read More ATRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATRX Stock News HeadlinesJanuary 30, 2024 | investing.comAdhera Therapeutics Inc (ATRX)August 24, 2023 | seekingalpha.comATRX Adhera Therapeutics, Inc.July 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.May 22, 2023 | seekingalpha.comIntensity Therapeutics upsizes proposed IPO to $15M from $8MFebruary 27, 2023 | finance.yahoo.comAdhera Therapeutics, Inc. (ATRX)January 25, 2023 | finance.yahoo.comAdhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 DiabetesJanuary 18, 2023 | seekingalpha.comCGTX Cognition Therapeutics, Inc.December 5, 2022 | seekingalpha.comAdhera Therapeutics files for Nasdaq uplisting, $35M offeringJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! October 9, 2022 | benzinga.comAdhera Therapeutics Stock (OTC:ATRXD), Analyst Ratings, Price Targets, PredictionsSeptember 21, 2022 | benzinga.comAdhera Therapeutics Announces CEO, Senior...September 19, 2022 | finance.yahoo.comAdhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ UplistSeptember 19, 2022 | seekingalpha.comAdhera Therapeutics gains on announcing CEO, senior management changes, plans for NASDAQ uplistJuly 19, 2022 | finance.yahoo.comAdhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium TransferrinMay 19, 2022 | seekingalpha.comAdhera Therapeutics appoints new Chairman of the Board, focuses on uplist to NasdaqMay 19, 2022 | finance.yahoo.comAdhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQJanuary 20, 2022 | finance.yahoo.comAdhera Therapeutics Announces Uplisting to OTCQB Venture MarketplaceNovember 22, 2021 | finance.yahoo.comAdhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related DisordersSee More Headlines Receive ATRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adhera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:ATRX CUSIPN/A CIK737207 Webadherathera.com Phone919-518-3748Fax206-830-9424Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($7.02) per share Price / Book0.00Miscellaneous Outstanding Shares11,630,000Free Float8,348,000Market Cap$93,040.00 OptionableNot Optionable Beta0.24 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Andrew Albert Kucharchuk M.B.A. (Age 43)Vice Chairman, COO, Acting CFO & Chief Business Officer Comp: $285kKey CompetitorsWellness Center USAOTCMKTS:WCUISciSparcNASDAQ:SPRCTherapix BiosciencesOTCMKTS:TRPXDRespireRx PharmaceuticalsOTCMKTS:RSPIeFFECTOR TherapeuticsNASDAQ:EFTRView All Competitors ATRX Stock Analysis - Frequently Asked Questions How have ATRX shares performed this year? Adhera Therapeutics' stock was trading at $0.03 at the beginning of 2024. Since then, ATRX shares have decreased by 73.3% and is now trading at $0.0080. View the best growth stocks for 2024 here. When did Adhera Therapeutics' stock split? Adhera Therapeutics's stock reverse split before market open on Thursday, October 6th 2022. The 1-20 reverse split was announced on Thursday, October 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Adhera Therapeutics? Shares of ATRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Adhera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adhera Therapeutics investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT) and Abiomed (ABMD). This page (OTCMKTS:ATRX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adhera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adhera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
